The company will use the funding to distribute its flagship ArteraAI Prostate Test, which predicts therapy benefit in localized prostate cancer.
Additionally, Artera will look to develop tests that support therapy personalization for other cancers, according to a March 21 Artera news release.
“The American Cancer Society estimates that more than 288,000 new cases of prostate cancer will arise in 2023, with more than 34,000 deaths. AI has given clinicians and patients a powerful weapon in the fight against this disease,” Andre Esteva, co-founder and CEO of Artera, said in the release. “Clinicians can now leverage Artera’s unique test to prognosticate patient outcomes and personalize treatment decisions.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
